Brief: Verrica Pharmaceuticals Posts Q2 Non-GAAP Loss Per Share $0.32
11/08/2022 14:56
Aug 11 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O :
* VERRICA PHARMACEUTICALS REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS
* REAFFIRMS PLANS TO RESUBMIT NDA FOR VP-102 FOR MOLLUSCUM
CONTAGIOSUM IN Q1 2023
* Q2 NON-GAAP LOSS PER SHARE $0.32
Source text for Eikon: ID:nGNX3WfBSb
Further company coverage: VRCA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data